๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Effect of adjuvant chemo- or immunotherapy on the prognosis of colorectal cancer operated for cure

โœ Scribed by Dr. M. Wunderlich; R. Schiessel; H. Rainer; R. Rauhs; E. Kovats; M. Schemper; Ch. Dittrich; M. Micksche; H. H. Sedlacek


Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
467 KB
Volume
72
Category
Article
ISSN
0007-1323

No coin nor oath required. For personal study only.

โœฆ Synopsis


immunotherapy on the prognosis of colorectal cancer operated for cure

After radical surgery for colorectal cancer, 178 patients with a Dukes' B or C tumour were randomly assigned to one of three groups: A , controls (n=62); B, chemotherapy (n=59); C, immunotherapy (n =57). Randomization criteria (age, sex, Dukes' stage, localization of tumour, operative procedure) were evenly distributed throughout the groups. After a median observation time of 30 months, statistical analyses were performed: survival and probability to be free of recurrence was described by Kaplan-Meier estimates of the survival function; for com arison of these survival functions, Breslow 's test compared to controls. Separate analyses by Dukes' stages showed that in patients with Dukes' C tumours the probability of survival 40 months after surgery was 72 per cent in group C, 51 per cent in group B, and 33 per cent in group A. The differences between groups C and A , and B and A were statistically significant (P<0-02 and P<0.03 respectively). For a Dukes' C tumour the probability to be free of distant metastases at 30 months after surgery was 80 per cent in group B, 68 per cent in group C and 52 per cent in roup A . Also for a months after surgery was 83 per cent in group B, 81 per cent in group C, and 54 per cent in group A (significant differences: B-A and C-A P<0-04 for both). There was no influence on the estimated incidence of local recurrences for stage Dukes' C. Patients with a Dukes' B tumour did not benefit from either of the adjuvant therapy schemes. was used. Overal P analyses show no benefit in the treatment group Dukes' C tumour the probability to be free of k iver metastases at 21


๐Ÿ“œ SIMILAR VOLUMES